ALKS
Alkermes plc.
Overview
Alkermes plc develops and commercializes biopharmaceutical products for neuroscience disorders. The company markets proprietary medications for schizophrenia, bipolar I disorder, narcolepsy, alcohol dependence, and opioid dependence, while also licensing its drug-delivery technologies to partners like Janssen and Biogen.
Alkermes plc is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $7.67B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 3, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-0519 Q&A exchanges
- Q4 FY2025Earnings2026-02-25
- Q3 FY2025Earnings2025-10-2818 Q&A exchanges
- Q2 FY2025Earnings2025-07-2919 Q&A exchanges
- Q1 FY2025Earnings2025-05-0125 Q&A exchanges
- Q4 FY2024Earnings2025-02-1226 Q&A exchanges
- Q3 FY2024Earnings2024-10-2424 Q&A exchanges
- Q2 FY2024Earnings2024-07-2426 Q&A exchanges
- Q1 FY2024Earnings2024-05-0121 Q&A exchanges
- Q4 FY2023Earnings2024-02-1521 Q&A exchanges
- Q3 FY2023Earnings2023-10-2514 Q&A exchanges
- Q2 FY2023Earnings2023-07-2618 Q&A exchanges
- Q1 FY2023Earnings2023-04-2618 Q&A exchanges
- Q4 FY2022Earnings2023-02-1624 Q&A exchanges
- Q3 FY2022Earnings2022-11-0218 Q&A exchanges
- Q2 FY2022Earnings2022-07-2718 Q&A exchanges
- Q1 FY2022Earnings2022-04-2711 Q&A exchanges
- Q4 FY2021Earnings2022-02-1615 Q&A exchanges
- Q3 FY2021Earnings2021-10-2715 Q&A exchanges
- Q2 FY2021Earnings2021-07-2820 Q&A exchanges
- Q1 FY2021Earnings2021-04-2815 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-03EPS— vs $-0.04—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-03 | — | $-0.04 | — | — | — | — | EODHD |
Source: EODHD. ALKS reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks ALKS's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 80% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.84 | $1.40 | +31.2% | +0.9% | +2.8% |
| Q4 FY2026 | $2.00 | $1.38 | +44.6% | -4.9% | -7.5% |
| Q3 FY2026 | $1.89 | $1.35 | +39.9% | -9.9% | -8.0% |
| Q2 FY2026 | $1.95 | $1.37 | +42.3% | +1.6% | +1.6% |
| Q1 FY2025 | $1.77 | $1.35 | +30.8% | -0.9% | -0.5% |
| Q4 FY2025 | $1.72 | $1.30 | +32.1% | -9.5% | -8.3% |
| Q3 FY2025 | $1.96 | $1.48 | +32.5% | -1.8% | -1.9% |
| Q2 FY2025 | $1.84 | $1.37 | +34.6% | -9.4% | -10.3% |
| Q1 FY2024 | $1.85 | $1.40 | +32.1% | -5.7% | -7.2% |
| Q4 FY2024 | $1.97 | $1.39 | +41.6% | -5.3% | -5.2% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Richard F PopsCEO4 mo21 callsCurrentSample
CEO since 2026 • 1/2 beats (50%) • last guidance cut Q1 FY2026
- Joshua ReedCFO3 mo3 callsCurrentSample
CFO since 2026 • 1/2 beats (50%) • last call held guidance Q1 FY2026
- Blair Curtis JacksonCOO4 mono recorded callsCurrentSample
COO since 2026 • 1/2 beats (50%) • last guidance cut Q3 FY2026
- David Joseph GaffinEVP, CLO, Alkermes, Inc.4 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 1/2 beats (50%) • last guidance cut Q3 FY2026
- Christian Todd NicholsSVP, Chief Commercial Officer4 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 1/2 beats (50%) • guidance suspended Q3 FY2026
- Craig C HopkinsonEVP R&D, Chief Medical Officer8 mo4 callsCurrentSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • guidance suspended Q2 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ALKS.
$ curl https://api.spokenalpha.com/v1/companies/ALKSFAQ
Frequently asked about ALKS
Where can I find Alkermes plc.'s (ALKS) earnings call transcripts?
Spoken Alpha indexes ALKS's earnings call transcripts at https://spokenalpha.com/companies/ALKS. Each call links to attributed speakers and parsed analyst Q&A. Alkermes plc.'s own investor relations page is at https://investor.alkermes.com/.
When was Alkermes plc.'s most recent earnings call?
Alkermes plc. (ALKS) held its most recent earnings call on 2026-05-05, covering fiscal Q1 2026.
What sector is ALKS in?
Alkermes plc. (ALKS) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).